Which rare diseases your newborn is screened for depends entirely on which state you were born in

The federal Recommended Uniform Screening Panel (RUSP) lists conditions that all states should screen newborns for, but states are not required to adopt the full panel, and many don't. The result is a geographic lottery. A baby born in New York gets screened for over 60 conditions. A baby born across the river in New Jersey may not be screened for the same set. Krabbe disease -- a devastating neurodegenerative condition where early stem cell transplant before symptom onset can preserve the ability to walk and talk -- was screened in only about 10 states before it was finally added to the RUSP in July 2024. Arthur Hutchinson, a child with Krabbe disease, was diagnosed only after he mysteriously stopped crawling. By then, it was too late for the transplant to restore full function. He was born in a state that didn't screen for Krabbe. The consequences of this inconsistency are not theoretical. Spinal muscular atrophy (SMA) was added to the RUSP in 2018, and states took years to implement screening. A 2024 study found significant variation in SMA screening practices across states, with inconsistencies in how results are reported and confirmed, and at least two states with high false-positive rates. For conditions like SMA where gene therapy (Zolgensma) must be administered before motor neurons degenerate, a delay of even weeks can mean the difference between a child who walks and one who doesn't. The structural barrier is that each state runs its own newborn screening program with its own funding, its own laboratory infrastructure, and its own political priorities. Adding a new condition requires legislative or regulatory action at the state level, and advocacy groups must fight 50 separate battles. Making matters dramatically worse, the Trump Administration disbanded the Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC) in April 2025 -- the only federal body that evaluated evidence and recommended conditions for the RUSP. Without this committee, there is currently no mechanism to add new conditions to the federal panel, meaning the pipeline of life-saving screenings has been frozen at the federal level while states remain free to do nothing.